Cargando…

Fulvestrant May Falsely Increase 17β-Estradiol Levels in Immunoassays: A Case Report of a 57-Year-Old Postmenopausal Patient With Recurrent Estrogen Receptor-Positive Breast Cancer

The prognosis for female patients with locoregionally recurrent breast cancer has improved with the concurrent local and systemic treatment under multiple disciplinary teams. Radiotherapy is a valuable local treatment measure for unresectable locoregional recurrent breast cancer; however, reirradiat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Jingxian, Cao, Yali, Guo, Yonghong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045700/ https://www.ncbi.nlm.nih.gov/pubmed/35494071 http://dx.doi.org/10.3389/fonc.2022.832763

Ejemplares similares

Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review
por: Ding, Jingxian, et al.
Publicado: (2020)

Oral estrogen leads to falsely low concentrations of estradiol in a common immunoassay
por: Cirrincione, Lauren R, et al.
Publicado: (2022)

A method to detect fulvestrant interference in estradiol in breast cancer patients
por: Brito, Margarida, et al.
Publicado: (2023)

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
por: Blancas, I., et al.
Publicado: (2021)

17β-estradiol lowers triglycerides in adipocytes via estrogen receptor α and it may be attenuated by inflammation
por: Luo, Fei, et al.
Publicado: (2017)

Serum estradiol level according to dose and formulation of oral estrogens in postmenopausal women
por: Kim, Soo-Min, et al.
Publicado: (2021)

The Antiestrogens Tamoxifen and Fulvestrant Abolish Estrogenic Impacts of 17α-ethinylestradiol on Male Calling Behavior of Xenopus laevis
por: Hoffmann, Frauke, et al.
Publicado: (2012)

During development, 17alpha-estradiol is a potent estrogen and carcinogen.
por: Hajek, R A, et al.
Publicado: (1997)

Modulation of uterine morphology and growth by estradiol-17beta and an estrogen antagonist
Publicado: (1975)

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2014)

Endoxifen and fulvestrant regulate estrogen-receptor α and related DEADbox proteins
por: Asberger, Jasmin, et al.
Publicado: (2020)

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
por: García-Sáenz, José Á., et al.
Publicado: (2022)

Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition
por: Kantarci, Kejal, et al.
Publicado: (2016)

False hyperthyroidism caused by interference in immunoassays
por: Jiménez García, Clara, et al.
Publicado: (2020)

Fulvestrant-Mediated Inhibition of Estrogen Receptor Signaling Slows Lung Cancer Progression
por: Tang, Hexiao, et al.
Publicado: (2014)

Estrogen Receptor Alpha Polymorphisms, Estradiol Level, and Occurrence of Atherosclerosis Risk Factors in Healthy Postmenopausal Women
por: Bojar, Iwona, et al.
Publicado: (2015)

Cognitive Functions, Concentration of Endogenous Estradiol, Estrogen Receptor α (ERα) Polymorphism in Postmenopausal Women
por: Bojar, Iwona, et al.
Publicado: (2016)

Conjugated equine estrogen used in postmenopausal women associated with a higher risk of stroke than estradiol
por: Chang, Wei-Chuan, et al.
Publicado: (2021)

Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients
por: Jaque, Jenny, et al.
Publicado: (2013)

1036 Estrogen Hormone Replacement Therapy May Lower Risk of Recurrent Urinary Tract Infections in Postmenopausal Women
por: Dickter, Jana, et al.
Publicado: (2014)

The Effects of 17β-estradiol in Cancer are Mediated by Estrogen Receptor Signaling at the Plasma Membrane
por: Acconcia, Filippo, et al.
Publicado: (2011)

Neuroprotective Effects of 17β-Estradiol Rely on Estrogen Receptor Membrane Initiated Signals
por: Fiocchetti, Marco, et al.
Publicado: (2012)

Quantum Dot-Sensitised Estrogen Receptor-α-Based Biosensor for 17β-Estradiol
por: Jijana, Abongile N., et al.
Publicado: (2023)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

Efficacy of Fulvestrant in Heavily Pretreated Postmenopausal Women with Advanced Breast Cancer: A Preliminary Report
por: Yoo, Changhoon, et al.
Publicado: (2011)

Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China
por: Zhang, Qingyuan, et al.
Publicado: (2016)

Simultaneous Degradation of Estrone, 17β-Estradiol and 17α-Ethinyl Estradiol in an Aqueous UV/H(2)O(2) System
por: Ma, Xiaoyan, et al.
Publicado: (2015)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Effects of 17β-Estradiol and Estrogen Receptor Antagonists on the Proliferation of Gastric Cancer Cell Lines
por: Kim, Myung-Jin, et al.
Publicado: (2013)

Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy
por: Minkin, Mary Jane, et al.
Publicado: (2013)

Challenges of measuring accurate estradiol levels in aromatase inhibitor‐treated postmenopausal breast cancer patients on vaginal estrogen therapy
por: Niravath, Polly, et al.
Publicado: (2017)

The Role of Airways 17β-Estradiol as a Biomarker of Severity in Postmenopausal Asthma: A Pilot Study
por: Scioscia, Giulia, et al.
Publicado: (2020)

Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial
por: Black, Denise R., et al.
Publicado: (2020)

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant
por: Kümler, Iben, et al.
Publicado: (2016)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

The truth about 17-beta estradiol: menopause beyond “old wives’ tales”
por: Nelson, Lawrence M.
Publicado: (2023)

57-Year-Old Male Veteran with Recurrent Fevers
por: Chu, Eileen, et al.
Publicado: (2023)

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

Association of Vaginal Estradiol Tablet With Serum Estrogen Levels in Women Who Are Postmenopausal: Secondary Analysis of a Randomized Clinical Trial
por: Mitchell, Caroline M., et al.
Publicado: (2022)

Differential Regulation of Dopamine Transporter Function and Location by Low Concentrations of Environmental Estrogens and 17β-Estradiol
por: Alyea, Rebecca A., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_2braee9gda6l7g32v4g1u7kjsk